Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Head & Neck 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Vipoma 1Uveal Melanoma 1Somatostatinoma 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gastrinoma 1Esthesioneuroblastoma, Olfactory 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Everolimus 10lanreotide 4Capecitabine 4pasireotide 3lutetium Lu 177 dotatate 3lenvatinib 3fosbretabulin 3Temozolomide 3Sorafenib 3Paclitaxel 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Filgrastim 3Erlotinib Hydrochloride 3Doxorubicin 3trifluridine tipiracil drug combination 2surufatinib 2pembrolizumab 2pegfilgrastim 2gallium Ga 68 dotatate 2durvalumab 2dactolisib 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Sunitinib 2Rosiglitazone 2Radiotherapy 2Panobinostat 2Mitotane 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × pentetreotide × Endocrine × Clear all
NCT00002947 2014-07-02

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Yale University

Phase 1 Terminated
35 enrolled
CNSDermatologicEndocrineGenitourinaryHead & NeckThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Vipoma, Glucagonoma, Head and Neck Neoplasms, Insulinoma, Adenoma, Islet Cell, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Central Nervous System Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡